You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Clinical Development of a Therapeutic Agent for COPD

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NHLBI

    DESCRIPTION (provided by applicant): Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases, including chronic pulmonary disease (COPD), asthma, cystic fibrosis, allergic rhinitis, and bronchiectasis.Despite the obvious medical importance, there presently are no effective therapies to control excess mucus secretion in these diseases, and very ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Clinical Development of a Therapeutic Agent for COPD

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NHLBI

    DESCRIPTION provided by applicant Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases including chronic pulmonary disease COPD asthma cystic fibrosis allergic rhinitis and bronchiectasis Despite the obvious medical importance there presently are no effective therapies to control excess mucus secretion in these diseases and very ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Photoacoustic CT for Preclinical Molecular Imaging

    SBC: OPTOSONICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of this collaborative research project is to commercialize a prototype photoacoustic computed-tomography (PCT) scanner for conducting preclinical molecular imaging. This scanner has been developed by OptoSonics with funding from a Fast Track SBIR grant from the National Cancer Institute (R44-CA-102891) and additional private funding fro ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Safe and effective anti CD154 antibodies for therapeutic intervention

    SBC: Immunext, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant In both animal proof of concept studies and preliminary clinical trials there is ample data demonstrating the potential therapeutic benefits o CD blockade for treatment of GVHD organ transplantation and autoimmune diseases However development of CD as a therapeutic has been impeded by antibody toxicity observed in early clinical trials GVHD is a ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Manufacturing Processes for Tissue Engineered Vascular Grafts

    SBC: HUMACYTE, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): This Phase IIB SBIR application is responsive to NHLBI RFA HL-13-016, NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood and Sleep Disorders and Diseases (R44) . This RFA solicits work on basic, applied, and clinical research on all product and service development related to the mission of the NHLBI. ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Manufacturing Processes for Tissue Engineered Vascular Grafts

    SBC: HUMACYTE, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant This Phase IIB SBIR application is responsive to NHLBI RFA HL andquot NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart Lung Blood and Sleep Disorders and Diseases R andquot This RFA solicits work on andquot basic applied and clinical research on all product and service development related to the ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Self Assembling High Affinity Peptides for Point of Care Drug-Device Combinations

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Infection surrounding metal implants is a common and sometimes devastating cause of implant failure in a number of fields including oral, craniomaxillofacial (CMF), orthopedic, and cardiovascular surgery. These infections, which arise from the establishment of biofilms on device surfaces, not only necessitate new surgeries but in themselves present a significan ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Commercialization of Human Mesothelial Cells for Research

    SBC: Zen-Bio, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Mesothelial cells have been found to be pivotal in tumor metastasis, peritoneal dialysis, and inflammatory response. These cells are specialized epithelial cells that line the peritoneal, pericardial, and pleural cavities and internal organs presenting a barrier to invading organisms and physical damage. Ovarian tumor attachments occur through cancer cells bind ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Formulations for Injectable Growth Factors

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Over 6.3 million fractures occur each year in the United States alone (Praemer et al. 1999) and approximately 15% of fractures exhibit delayed or impaired healing. The clinical applications currently used to treat delayed fracture require open surgery to insert an autologous bone graft. If open surgery is confounded by co-morbidity or is deemed otherwise undes ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic for the Negative Symptoms of Schizophrenia

    SBC: Darpharma, Inc.            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Schizophrenia affects roughly 1% of the world's population, with more than two million Americans afflicted in any given year, and an estimated 30-50 million people worldwide. Treatment with available antipsychotic medications often effectively attenuates the positive symptoms of schizophrenia without improvement in the negative symptoms or cognitive deficits. F ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government